Context Therapeutics (CNTX) Other Operating Expenses (2024 - 2026)

Context Therapeutics has disclosed Other Operating Expenses across 3 years of filings, most recently posting -$7.4 million for Q1 2026.

• Other Operating Expenses for Q1 2026 came in at -$7.4 million, down 66.48% year-over-year; the trailing twelve-month figure through Mar 2026 was -$37.6 million (down 33.1% YoY), and the FY2025 annual result was -$34.8 million, down 43.12% from the prior year.
• Other Operating Expenses came in at -$7.4 million for Q1 2026 at Context Therapeutics, up from -$12.4 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of -$1.9 million in Q1 2024 to a low of -$17.3 million in Q3 2024.
• The 3-year median for Other Operating Expenses is -$7.4 million (2026), against an average of -$7.5 million.
• Peak annual rise in Other Operating Expenses reached 45.73% in 2025, while the deepest fall reached 266.86% in 2025.
• Context Therapeutics' Other Operating Expenses stood at -$3.4 million in 2024, then sank by 266.86% to -$12.4 million in 2025, then surged by 40.15% to -$7.4 million in 2026.
• The last three Other Operating Expenses figures came in at -$7.4 million (Q1 2026), -$12.4 million (Q4 2025), and -$9.4 million (Q3 2025), per Business Quant data.